Ellab is Expanding in the US with the Acquisition of ICQ
Since 2007, ICQ has partnered with the world’s largest biopharma manufacturers and emerging life sciences companies to provide comprehensive commissioning, qualification, and validation (CQV) services that accelerate the delivery of medications and therapies to patients in need.
The acquisition of ICQ is a major step in the execution of Ellab’s corporate strategy of expanding its field services in key markets within the biopharma industry. Ellab has grown rapidly organically in the US since taking the successful strategic choice of expanding into validation services in late 2016.
With the addition of ICQ, Ellab US will expand from 120 to 180 employees. Including the ICQ team, Ellab’s global field service organization is now counting 330 employees and the total headcount for the Ellab Group is 720.
In addition to the combined field services and consulting services, ICQ and Ellab can offer a strong value proposition of validation, calibration, and monitoring solutions, across the entire US. With ICQ’s strong experience in CQV and industry specific project management and Ellab’s leading equipment and software, as well as strong brand, Ellab US will continue to rapidly grow its customer relationships and infrastructure.
“Being our first acquisition in the US, we are so excited to welcome ICQ into the Ellab family. With clear synergies in the expanded CQV Services we can offer to our respective clients, we will strengthen our position as a key strategic partner in the biopharma market. When two strong teams with fantastic cultures come together, the whole is clearly greater than the sum of its parts.” – Tim Paymaster, President and Chief Commercial Officer, Ellab, Inc.
The owners of ICQ, Michael Bogan, Michael Gatta and Alfonso Guarracino will continue within the management team in Ellab US.
This is Ellab’s first acquisition in the US and the 12th globally under EQT’s ownership. Working with EQT has allowed Ellab to continually welcome more great teams to join the Ellab family and grow to address customers’ needs across the globe.
Ellab provides world-leading validation, monitoring and calibration solutions and services, as well as GMP consulting, to life science and food manufacturing companies across the globe – allowing us to build confidence in consumer safety, together. In September 2019, Ellab was acquired by the EQT Mid-Market Europe Fund (“EQT”).
Visit Ellab’s website to read the original release and learn more.